In depth view into Akebia Therapeutics Price Target Upside (Daily) including historical data from 2014, charts, stats and industry comps. Entry level $4.41 = target price $5.14 Average analysts price target $14.86 | Buy Company profile Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The latest high is set lower that the high price recorded in the period of the last 52 weeks, set at -36.37%. AKBA updated stock price target summary. Stock Target Advisor runs millions of automatic calculations on over 75,000 stocks in American, Asian and European Exchanges and compares it with market analyst stock ratings and target stock prices to help you make smart investment decisions and build robust investment portfolios. Needham, on the other hand, stated in their research note that they expect to see AKBA reach a price target of $15, previously predicting the price at $18. They have a new drug in the pipeline and in May of last year announced the success of the Phase 3 trials in dialysis patients taking the stock price to $12 a share nearly. In terms of volatility of its share price, AKBA is more volatile than 95.62% of stocks we're observing. Get the latest Zacks research report on AKBA — FREE. As a result, AKBA is trading at a discount of 133.64% off the target high and -29.91% off the low. The current projected Akebia Therapeutics target price consensus is 10.17 with 6 analyst opinions. The consensus price target of analysts on Wall Street is $7, which implies an increase of 63.55% to the stock’s current value. View Price Target for AKBA Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Entry level $4.41 = target price $5.14 Average analysts price target $14.86 | Buy Company profile Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The rating they have provided for AKBA stocks is “Buy” according to the report published on November 14th, 2019. In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $6.00.The company’s shares closed last Thursday at $2.49, close to its 52-week low of $2.09. 10 ETFs With Most Upside To Analyst Targets Akebia Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Over the last 30 days, this security got 2 buy, 0 sell and 0 hold ratings. Already a subscriber? Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Akebia Therapeutics, Inc. (AKBA… AKBA Trading at 10.51% from the 50-Day Moving Average After a stumble in the market that brought AKBA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.16% of loss for the given period. In that case, then, we find that the latest price level in today’s session is +99.6% off the targeted high while a plunge would see the stock lose -40.12% from current levels. Compugen has an analyst consensus of Moderate Buy, with a price target consensus of $19.00. Sign in. See today’s analyst top recommended stocks >> Akebia Therapeutics (AKBA) In a report released today, Chad Messer from Needham maintained a Buy rating on Akebia Therapeutics, with a price target of $10.00. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00. Start My Free Trial No credit card required. In predicting price targets of as low as $3 and as high as $10, analysts are in agreement on assigning the stock over the next 12 months average price target of $7. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. The average price target represents a 252.25% upside from the last price of $2.92. HC Wainwright & Co. cut the price target for Akebia Therapeutics, Inc. (NASDAQ: AKBA) from $9 to $6. Akebia Therapeutics Stock Forecast, AKBA stock price prediction. The median AKBA price target (a different metric than the average or mean) was $8.5 as of 2021-01-27, the highest AKBA price target in the range was $18.0 while the lowest AKBA price target in the range was $3.0, with a standard deviation of $6.047. Akebia Therapeutics shares rose 0.2% to … Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Susquehanna raised Accenture plc (NYSE: ACN) price target from $267 to $290. 10 Biggest Price Target Changes For Monday. The Story . The AKBA stock was last observed hovering at around $2.99 in the last trading session, with the day’s gains setting it 0.08% off its average median price target of $7.00 for the next 12 months. Akebia Therapeutics (NASDAQ:AKBA) had its price objective decreased by HC Wainwright from $9.00 to $6.00 in a research report report published on Monday, The Fly reports. A number of other equities analysts have also recently commented on the stock. Start your free 7-Day Trial. Our price target ("PT") is $5.17, offering 99% upside. AKBA Stock Summary. View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Previously, the target price had yet another drop from $23 to $21, while H.C. Wainwright kept a Buy rating on AKBA stock. H.C. Wainwright gave a rating of “Buy” to AKBA, setting the target price at $17 in the report published on August 06th of the previous year. This price target is based on 7 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $10.29, with a high forecast of $18.00 and a low forecast of $3.00. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Akebia Therapeutics stock price target cut to $6 from $17 at Mizuho Sep. 4, 2020 at 6:22 a.m. Of note is the ratio of Akebia Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 22.54% of US stocks have a lower such ratio. It is also 69.3% off the consensus price target high of $10.00 offered by 7 analysts, but current levels are -2.33% lower than the price target low of $3.00 for the same period. The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.19, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 1.38. AKBA Highlights: Akebia is a biopharma specializing in nephrology focused drugs targeting chronic kidney disease. Based on analysts offering 12 month price targets for AKBA in the last 3 months. The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.25, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 1.42. Analysts’ Opinion of AKBA. The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.16, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 1.44. The 52-week high currently stands at 10.53 distance from the present share price, noting recovery -11.84% after the recent low of 2.99. Source: Seeking Alpha. Many experts also interview Akebia Therapeutics executives and customers to further validate their buy or sell advice. Akebia Therapeutics (NASDAQ:AKBA) Given New $6.00 Price Target at HC Wainwright americanbankingnews.com - March 9 at 12:30 AM: Akebia Therapeutics (NASDAQ:AKBA) Coverage Initiated by Analysts at Cantor Fitzgerald americanbankingnews.com - March 8 at 1:10 PM: Looking Into Akebia Therapeutics's Return On Capital Employed finance.yahoo.com - March 2 at 2:46 PM: Akebia … ET by Tomi Kilgore Akebia's shares jump on late-stage clinical trial results for kidney disease drug 1-Yr Stock Chart. The price target was set to $9.00 → $6.00. Accenture shares fell 0.6% to $247.93 in pre-market trading. Akebia Therapeutics (NASDAQ:AKBA) had its price objective raised by research analysts at Morgan Stanley from $11.00 to $12.00 in a report issued on Wednesday, BenzingaRatingsTable reports. Previously, the target price had yet another drop from $23 to $21, while H.C. Wainwright kept a Buy rating on AKBA stock. Previously, the target price had yet another drop from $23 to $21, while H.C. Wainwright kept a Buy rating on AKBA stock. JPMorgan Chase & Co. […] The most common way Akebia Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Safety Concern Offsets Chronic Kidney Disease Study Positive Results. We think AKBA is again a Strong Buy. The projected low price target is $3 while the price target rests at a high of $10. Today, HC Wainwright lowered its price target on Akebia Therapeutics Inc (NASDAQ:AKBA) to $21.00 per share. According to TipRanks.com, Yang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.1% and a 32.4% success rate. AKBA had two major price movements with the latest trading session as the price jumped to a high of $7.45, at one point touching $6.56. The extremes of the forecast give a target low and a target high price of $3 and $10 respectively. HC Wainwright is very positive to AKBA and gave it a "Buy" rating on March 08, 2021. Shar... 24/7 Wall Street - 6 months ago.
Circuit De Barcelona-catalunya Change, Street Map Of East Northport Ny, Code: Realize ~bouquet Of Rainbows~ Review, Lego 10225 Original Price, Cam Reconciliation Services, Lisa Manoban House In Korea, Jacksonville State University Dorm Virtual Tour,